-$0.52 EPS Expected for Rocket Pharmaceuticals Inc (NASDAQ:RCKT) This Quarter

Equities research analysts expect Rocket Pharmaceuticals Inc (NASDAQ:RCKT) to announce earnings of ($0.52) per share for the current fiscal quarter, Zacks reports. Zero analysts have made estimates for Rocket Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.69) and the highest is ($0.40). Rocket Pharmaceuticals posted earnings per share of ($0.66) in the same quarter last year, which indicates a positive year-over-year growth rate of 21.2%. The business is expected to announce its next quarterly earnings report on Thursday, March 5th.

On average, analysts expect that Rocket Pharmaceuticals will report full-year earnings of ($1.68) per share for the current year, with EPS estimates ranging from ($1.89) to ($1.54). For the next financial year, analysts forecast that the business will report earnings of ($2.28) per share, with EPS estimates ranging from ($3.45) to ($1.57). Zacks’ earnings per share averages are an average based on a survey of research firms that follow Rocket Pharmaceuticals.

Rocket Pharmaceuticals (NASDAQ:RCKT) last released its earnings results on Thursday, November 7th. The biotechnology company reported ($0.38) EPS for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.11.

A number of research analysts have weighed in on the company. ValuEngine lowered Rocket Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, November 1st. William Blair reaffirmed a “buy” rating on shares of Rocket Pharmaceuticals in a research report on Tuesday, September 10th. Oppenheimer dropped their target price on Rocket Pharmaceuticals from $39.00 to $37.00 and set an “outperform” rating for the company in a research note on Tuesday, August 13th. Chardan Capital reiterated a “buy” rating and set a $30.00 target price on shares of Rocket Pharmaceuticals in a research report on Friday. Finally, Cowen reissued a “buy” rating on shares of Rocket Pharmaceuticals in a research note on Sunday, November 17th. Two research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. Rocket Pharmaceuticals has a consensus rating of “Buy” and an average price target of $31.50.

Rocket Pharmaceuticals stock traded up $2.65 during trading hours on Friday, hitting $22.37. The stock had a trading volume of 1,002,018 shares, compared to its average volume of 242,551. Rocket Pharmaceuticals has a 1-year low of $10.75 and a 1-year high of $24.42. The stock has a market capitalization of $992.91 million, a price-to-earnings ratio of -11.83 and a beta of 2.78. The stock’s fifty day moving average is $15.56 and its two-hundred day moving average is $13.98. The company has a debt-to-equity ratio of 0.20, a current ratio of 11.07 and a quick ratio of 11.07.

Several large investors have recently modified their holdings of RCKT. Metropolitan Life Insurance Co NY grew its stake in shares of Rocket Pharmaceuticals by 43.4% in the third quarter. Metropolitan Life Insurance Co NY now owns 10,616 shares of the biotechnology company’s stock worth $124,000 after acquiring an additional 3,213 shares during the last quarter. Eventide Asset Management LLC raised its stake in shares of Rocket Pharmaceuticals by 42.3% during the third quarter. Eventide Asset Management LLC now owns 1,415,000 shares of the biotechnology company’s stock worth $16,485,000 after buying an additional 420,686 shares during the last quarter. Tower Research Capital LLC TRC raised its position in shares of Rocket Pharmaceuticals by 1,107.4% during the 3rd quarter. Tower Research Capital LLC TRC now owns 4,250 shares of the biotechnology company’s stock valued at $50,000 after acquiring an additional 3,898 shares during the last quarter. Comerica Bank raised its position in shares of Rocket Pharmaceuticals by 35.2% during the 3rd quarter. Comerica Bank now owns 28,155 shares of the biotechnology company’s stock valued at $363,000 after acquiring an additional 7,329 shares during the last quarter. Finally, California Public Employees Retirement System acquired a new stake in shares of Rocket Pharmaceuticals during the third quarter worth $168,000. Institutional investors and hedge funds own 93.86% of the company’s stock.

Rocket Pharmaceuticals Company Profile

Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating pediatric diseases. It has clinical-stage lentiviral vector (LVV) programs under clinical testing to treat fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; and leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction It also has additional pre-clinical stage LVV programs include pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia; and infantile malignant osteopetrosis, a genetic disorder characterized by increased bone density and bone mass secondary to impaired bone resorption.

See Also: How to calculate compound interest

Get a free copy of the Zacks research report on Rocket Pharmaceuticals (RCKT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Rocket Pharmaceuticals (NASDAQ:RCKT)

Receive News & Ratings for Rocket Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rocket Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.